Dr. Leath on Challenges With Bevacizumab in Cervical Cancer

Video

Charles A. Leath, III, MD, gynecologic oncologist, The University of Alabama at Birmingham, discusses challenges with bevacizumab in the treatment of patients with cervical cancer.

Charles A. Leath, III, MD, gynecologic oncologist, The University of Alabama at Birmingham, discusses challenges with bevacizumab (Avastin) in the treatment of patients with cervical cancer.

Investigators were initially excited to see that the combination of standard chemotherapy with the antiangiogenic agent bevacizumab did improve overall survival, but this is only a temporary survival benefit, Leath says. These patients will inevitably recur, and the median survival for these patients is somewhere between 4 months and 8 months.

Bevacizumab is a very expensive drug, although cost is becoming less of an issue as most payers are accepting coverage of it, Leath adds. However, the agent carries some significant toxicity concerns. Long-term follow-up data presented by Krishnansu S. Tewari, MD, of the University of California, Irvine, show fistula rates around 15%. This is critical to note, says Leath, because fistula rates usually require surgical intervention. Therefore, bevacizumab is providing non-curative therapy with a high toxicity rate.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD